Bristol-Myers, BDR Pharmaceuticals International Pvt. Ltd. cancer news

Attorneys for BDR Pharmaceuticals said Bristol-Myers filed an affidavit in the Delhi High Court on Aug. 26 indicating that BDR's application for a compulsory license for cancer drug Sprycel dasatinib had been rejected by India's Patent Controller. Gopakumar Nair Associates, the firm representing BDR, said the application is still pending. According to The Times of India, BDR applied for a compulsory license in February, after which BMS filed suit against the company for patent infringement. BMS said it does not comment on ongoing litigation. The court is scheduled to hear arguments on Sept. 27. ...